Evgeny M. Makarov

Evgeny M. Makarov

Auto-generated profile, based on publicly available information

Evgeny M. Makarov

Department of Cellular Biochemistry, Max Planck Institute of Biophysical Chemistry, D-37077 Göttingen, Germany

Research Focus & Metrics

Academic Career Length

47Years (1980-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2013 in Cell Communication and Signaling
Verified
Journal Article
Open access
PDF file
TSTatiana Shtam
Tatiana Shtam
RKRoman A Kovalev
Roman A Kovalev
EVElena Yu Varfolomeeva
Elena Yu Varfolomeeva
EMEvgeny M Makarov
Evgeny M Makarov
YKYury Kil
Yury Kil
MFMichael Filatov
Michael Filatov
Background: Exosomes are nano-sized vesicles of endocytic origin that are involved in cell-to-cell communication including shuttle RNA, mainly mRNA and microRNA. As exosomes naturally carry RNA between cells, these particles might be useful in gene cancer therapy to deliver therapeutic short interfering RNA (siRNA) to the target cells. Despite the promise of RNA interference (RNAi) for use in therapy, several technical obstacles must be overcome. Exogenous siRNA is prone to degradation, has a limited ability to cross cell membranes and may induce an immune response. Naturally occurring RNA carriers, such as exosomes, might provide an untapped source of effective delivery strategies. Results: This study demonstrates that exosomes can deliver siRNA to recipient cells in vitro. The different strategies were used to introduce siRNAs into human exosomes of various origins. The delivery of fluorescently labeled siRNA via exosomes to cells was confirmed using confocal microscopy and flow cytometry. Two different siRNAs against RAD51 and RAD52 were used to transfect into the exosomes for therapeutic delivery into target cells. The exosome-delivered siRNAs were effective at causing post-transcriptional gene silencing in recipient cells. Moreover, the exosome-delivered siRNA against RAD51 was functional and caused the massive reproductive cell death of recipient cancer cells. Conclusions: The results strongly suggest that exosomes effectively delivered the siRNA into the target cells. The therapeutic potential of exosome-mediated siRNA delivery was demonstrated in vitro by the strong knockdown of RAD51, a prospective therapeutic target for cancer cells. The results give an additional evidence of the ability to use human exosomes as vectors in cancer therapy, including RNAi-based gene therapy.

13 December 2002 in Science
Verified
Journal Article
Closed access
PDF file
EMEvgeny M. Makarov
Evgeny M. Makarov
OMOlga V. Makarova
Olga V. Makarova
HUHenning Urlaub
Henning Urlaub
MGMarc Gentzel
Marc Gentzel
CWCindy L. Will
Cindy L. Will
RLReinhard Lührmann
Reinhard Lührmann
Major structural changes occur in the spliceosome during its activation just before catalyzing the splicing of pre–messenger RNAs (pre-mRNAs). Whereas changes in small nuclear RNA (snRNA) conformation are well documented, little is known about remodeling of small nuclear ribonucleoprotein (snRNP) structures during spliceosome activation. Here, human 45 S activated spliceosomes and a previously unknown 35 S U5 snRNP were isolated by immunoaffinity selection and were characterized by mass spectrometry. Comparison of their protein components with those of other snRNP and spliceosomal complexes revealed a major change in protein composition during spliceosome activation. Our data also suggest that the U5 snRNP is dramatically remodeled at this stage, with the Prp19 complex and other factors tightly associating, possibly in exchange for other U5 proteins, and suggest that after catalysis the remodeled U5 is eventually released from the postsplicing complex as a 35 S snRNP particle.

1 January 2012 in Nature Communications
Verified
Journal Article
Open access
PDF file
CGCyrille Girard
Cyrille Girard
CWCindy L. Will
Cindy L. Will
JPJianhe Peng
Jianhe Peng
EMEvgeny M. Makarov
Evgeny M. Makarov
BKBerthold Kastner
Berthold Kastner
RLReinhard Lührmann
Reinhard Lührmann
There is little quantitative information regarding how much splicing occurs co-transcriptionally in higher eukaryotes, and it remains unclear where precisely splicing occurs in the nucleus. Here we determine the global extent of co- and post-transcriptional splicing in mammalian cells, and their respective subnuclear locations, using antibodies that specifically recognize phosphorylated SF3b155 (P-SF3b155) found only in catalytically activated/active spliceosomes. Quantification of chromatin- and nucleoplasm-associated P-SF3b155 after fractionation of HeLa cell nuclei, reveals that ~80% of pre-mRNA splicing occurs co-transcriptionally. Active spliceosomes localize in situ to regions of decompacted chromatin, at the periphery of or within nuclear speckles. Immunofluorescence microscopy with anti-P-SF3b155 antibodies, coupled with transcription inhibition and a block in splicing after SF3b155 phosphorylation, indicates that post-transcriptional splicing occurs in nuclear speckles and that release of post-transcriptionally spliced mRNA from speckles is coupled to the nuclear mRNA export pathway. Our data provide new insights into when and where splicing occurs in cells.

15 May 2001 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
OMOlga V. Makarova
Olga V. Makarova
EMEvgeny M. Makarov
Evgeny M. Makarov
RLReinhard Lührmann
Reinhard Lührmann
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

3 June 2004 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
OMOlga V Makarova
Olga V Makarova
EMEvgeny M Makarov
Evgeny M Makarov
HUHenning Urlaub
Henning Urlaub
CWCindy L Will
Cindy L Will
MGMarc Gentzel
Marc Gentzel
RLReinhard Lührmann
Reinhard Lührmann
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

22 March 2000 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
JVJ.P. Venables
J.P. Venables
DEDavid Elliott
David Elliott
OMO.V. Makarova
O.V. Makarova
EME.M. Makarov
E.M. Makarov
HCH.J. Cooke
H.J. Cooke
IEI.C. Eperon
I.C. Eperon
The RBMY gene family is found on the Y chromosome of all mammals, and microdeletions are strongly associated with infertility in men. RBMY expresses RBM only in the nuclei of germ cells, whereas its X chromosome homologue, RBMX, expresses hnRNP G ubiquitously. We show here that RBM, hnRNP G and a novel testis-specific relative, termed hnRNP G-T, interact with Tra2β, an activator of pre-mRNA splicing that is ubi­quitous but highly expressed in testis. Endogenous hnRNP G and Tra2β proteins are associated in HeLa nuclear extracts. RBM and Tra2β co-localize in two major domains in human spermatocyte nuclei. Phosphorylation enhanced the interaction and reduced competing RNA binding to the interaction domains. Incubation with the protein interaction domain of RBM inhibited splicing in vitro of a specific pre-mRNA substrate containing an essential enhancer bound by Tra2β. The RNA-binding domain of RBM affected 5′ splice site selection. We conclude that the hnRNP G family of proteins is involved in pre-mRNA splicing and infer that RBM may be involved in Tra2β-dependent splicing in spermatocytes.